Previous studies stated that identification of p16 protein expression directly correlates with the tumor behavior and tumor stage where the low-grade tumors and the NMIBCs showed a high expression rate of p16 protein which may help in the process of selecting patients for an early aggressive therapy [13,18]. The gene discussed is CDKN2A; the disease is neoplasm.